India’s Decision To Uphold Natco’s Compulsory License On Nexavar Holds Key Lessons For Innovators, Generic Makers
This article was originally published in PharmAsia News
Executive Summary
The 48-page judgment points at several issues ranging from the nuances of claims and rejections of licenses to what can be seen as “reasonably affordable.”